Sourcing
We see opportunities through operating relationships across the United States — not intermediated deal flow. Proprietary access lets us take time on the questions that matter.
Approach
Most capital is underwritten to a story. We underwrite to a distribution — and we treat the terms of a deal as inseparable from the quality of the business behind it.
How we underwrite
We model outcome distributions rather than single-point projections. A position is underwritten to the shape of what can happen, not to the midpoint of a pitch deck.
We underwrite to conservative cases rather than sponsor forecasts. If the numbers only work in the bull case, we treat that as an answer, not a starting point.
Liquidation preference, dilution, fee structure, and liquidity determine realized returns as much as the underlying company. We weight terms accordingly.
Conviction sets direction; the distribution sets size. We would rather miss a good company than overpay for one.
“We would rather miss a good company than overpay for one.”
The process
We see opportunities through operating relationships across the United States — not intermediated deal flow. Proprietary access lets us take time on the questions that matter.
We build the model ourselves. Regulatory status, clinical or contractual data, competitive replication cost, and the specific mechanics of each market are tested independently of the sponsor's materials.
We participate directly or through special purpose vehicles alongside institutional leads, and we negotiate terms — preference, fees, information rights, liquidity — with the same rigor we apply to the business.
After the investment, we stay close to the metrics that move the distribution and support portfolio companies as they scale into regulated US enterprise, healthcare, and government markets.
If your company sits behind a real barrier, we would like to understand it.
Start a conversation →